Histocell, a company from Biscay in which Seed Capital Bizkaia participates, will shortly start the clinical trial of its cell therapy drug at Cruces Hospital with a group of 26 patients with respiratory problems caused by COVID-19.

People affected with respiratory distress (ARDS) derived from Covid-19 infection meet the criteria to participate in this Clinical Trial that aims to help the patient overcome the ARDS situation, as well as decrease the mortality rate and the damages caused in the medium/long-term in lung tissue. 

ARDS, the most serious complication

More than 40% of severely hospitalized people develop ARDS, and about 50% with moderate-severe ARDS dies due to this syndrome. Therefore, these data show that Acute Respiratory Distress Syndrome (ARDS) represents the most serious complication of Covid-19 infection.

HC016, the result of a long development work

Histocell has been developing for years a cell therapy drug for ARDS, called HC016, based on adult stem cells obtained from adipose tissue designed to survive in highly inflammatory environments. Thus, HC016 cells are especially suitable for the treatment of ARDS that appears in people with Covid-19.